Article Text
PDFCorrection
Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Statistics from Altmetric.com
Mandalá M, Larkin J, Ascierto PA, et al. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. J ImmunoTher Cancer 2021;9:e003188. doi: 10.1136/jitc-2021-003188.
This article has been corrected since it was first published. Author name has been corrected from 'Ivan Marquez' to 'Ivan Marquez-Rodas'.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.